Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation |
| |
Authors: | Y. Le Meur ,M. Bü chler,A. Thierry,S. Caillard,F. Villemain,S. Lavaud,I. Etienne,P.-F. Westeel,B. H. de Ligny,L. Rostaing,E. Thervet,J. C. Szelag,J.-P. Ré rolle,A. Rousseau,G. Touchard, P. Marquet |
| |
Affiliation: | Department of Nephrology, University Hospital, Limoges, France. yannick.lemeur@chu-brest.fr |
| |
Abstract: | Efficacy and safety of mycophenolate mofetil (MMF) may be optimized with individualized doses based on therapeutic monitoring of its active metabolite, mycophenolic acid (MPA). In this 12-month study, 137 renal allograft recipients from 11 French centers receiving basiliximab, cyclosporine A, MMF and corticosteroids were randomized to receive either concentration-controlled doses or fixed-dose MMF. A novel Bayesian estimator of MPA AUC based on three-point sampling was used to individualize doses on posttransplant days 7 and 14 and months 1, 3 and 6. The primary endpoint was treatment failure (death, graft loss, acute rejection and MMF discontinuation). Data from 65 patients/group were analyzed. At month 12, the concentration-controlled group had fewer treatment failures (p = 0.03) and acute rejection episodes (p = 0.01) with no differences in adverse event frequency. The MMF dose was higher in the concentration-controlled group at day 14 (p < 0.0001), month 1 (p < 0.0001) and month 3 (p < 0.01), as were median AUCs on day 14 (33.7 vs. 27.1 mg*h/L; p = 0.0001) and at month 1 (45.0 vs. 30.9 mg*h/L; p < 0.0001). Therapeutic MPA monitoring using a limited sampling strategy can reduce the risk of treatment failure and acute rejection in renal allograft recipients 12 months posttransplant with no increase in adverse events. |
| |
Keywords: | Area-under-curve mycophenolate mofetil renal transplantation therapeutic drug monitoring |
|
|